Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022
· ATOR-1017 demonstrates an excellent clinical profile as a potential best-in-class 4-1BB monoclonal antibody · ATOR-1017 was safe and well tolerated at doses up to 600 mg · No dose-limiting toxicity was observed and maximum tolerated dose was not reached · Stable disease was achieved in 45% of patients with solid tumors · Dose escalation continues at 900 mg dose level Lund, Sweden, May 31, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces it will present a poster on the 4-1BB conditional agonist antibody ATOR-1017 at the 2022 ASCO (American Society of